This episode of Drug Digest will discuss where the significant bottlenecks are in the development and manufacturing of new molecules resulting from progressive technologies, such as AI and ML, and how best to approach these challenges.
Register Free: https://www.pharmtech.com/pt_w/progressive-technologies
Event Overview:
The biopharma industry is at a time where progressive technologies such as artificial intelligence, machine learning, and digitalization technologies are making a significant impact on how drug discovery, development, and manufacturing are being driven. Yet the question remains as to how the industry itself is keeping up with the fast-paced innovation churning out from these advanced technologies. This episode of Drug Digest will examine where the significant bottlenecks are in the development and manufacturing of new molecules resulting from these progressive technologies, and how best to approach these challenges.
Key Learning Objectives:
Where current focus is by industry participant in terms of clinical development
Identify key bottlenecks in the drug discovery process, development phases, and manufacturing
A possible preview of some of the most promising modalities for future development
What the impact will be on the biomanufacturing sector, in particular
Who Should Attend:
CROs
CDMOs/CMOs
Startup biotechs/emerging biotechs
Analytical instrument providers
Speakers:
Kevin Dondarski
Principal, Life Sciences R&D
Deloitte Consulting
Kevin Dondarski is a principal within Deloitte Consulting’s Life Sciences R&D practice. He has more than 20 years of experience advising clients on R&D strategy, R&D productivity, and portfolio management/capital allocation. He holds a Bachelor of Science and Master of Science in biochemical engineering from Rutgers University, and a Master of Business Administration in finance and managerial economics from the Kellogg School of Management at Northwestern University.
Maryland Franklin, PhD
Vice-President and Enterprise Head, Cell and Gene Therapy
Labcorp
Maryland Franklin is vice-president and enterprise head of Cell and Gene Therapy at Labcorp, leading strategy and development. She joined Labcorp in 2019 through an acquisition, having led a preclinical oncology contract research organization team driving scientific and business success. Prior to this, with 12 years in biopharma, she helped advance multiple therapeutics, including four into Phase I trials.
Franklin holds a PhD in medical genetics from the University of Alabama at Birmingham where she focused on cancer gene therapy research.
Lidia Serina, PhD
Head of Development Services
Simtra BioPharma Solutions
Lidia Serina, PhD, is head of Development Services at Simtra BioPharma Solutions, leading a strategic area essential to the company’s mission. She partners with clients to develop high-quality injectable products and efficient manufacturing processes. With extensive experience in supply chain, vaccine R&D, quality and regulatory compliance, and both commercial and clinical manufacturing, Serina’s technical expertise spans a wide range of molecule types. Her leadership drives innovative solutions to the complex challenges of product development and manufacturing.
Sean Tucker, PhD
Founder and Chief Scientific Officer
Vaxart
Sean Tucker, PhD, is the founder of Vaxart and has served as its chief scientific officer since February 2010. From March 2004 to February 2010, Tucker served as vice-president of Research and director of Immunology. He has held numerous scientific and engineering roles at various biotechnology companies. Tucker has a Bachelor of Science in chemical engineering from the University of Washington, a Master of Science in chemical engineering from the University of California, Berkeley, and a PhD in immunology from the University of Washington.
Register Free: https://www.pharmtech.com/pt_w/progressive-technologies